Oncology Liquid biopsy and the future of tumour-agnostic treatments Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.
Oncology After Pluvicto: Alpha radiopharma and prostate cancer Dr Philip Kantoff, a world-renowned prostate cancer clinician and researcher, discusses alpha radiopharma treatment possibilities.
News Review advises against broad NHS prostate cancer screening The UK's National Screening Committee has concluded that the harms of widespread prostate cancer screening would outweigh its benefits.
R&D Human behaviour in cancer screening trials: A variable that ... Behavioural phenomena are particularly consequential in screening and prevention research in oncology.
News AI predicts liver cancer risk with "high accuracy" A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.
News Denying prostate cancer screening 'no longer rational' A German study has stoked debate about the merits of screening for prostate cancer, which is lagging behind breast cancer screening in Europe.
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
